KalVista Pharmaceuticals (KALV) Interest & Investment Income (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Interest & Investment Income of $18000.0 for Q3 2025, down 98.94% on a YoY basis from $1.7 million in Q3 2024, and down 93.48% sequentially from $276000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Interest & Investment Income (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Interest & Investment Income data on file, last reported at $18000.0 in Q3 2025.
- For the quarter ending Q3 2025, Interest & Investment Income fell 98.94% year-over-year to $18000.0; the trailing twelve-month figure through Jul 2025 stood at $2.6 million (down 49.25% YoY), and the FY2025 full-year result was $2.4 million, down 39.48% from the prior year.
- Interest & Investment Income retreated to $18000.0 in Q3 2025, from $276000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.6 million in Q2 2024 to a low of -$2.3 million in Q2 2022.
- A 5-year average of $286444.4 and a median of $267000.0 in 2022 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income tumbled 2480.0% in 2021 and surged 746.15% in 2023, its largest moves.
- Tracing KALV's Interest & Investment Income over 5 years: stood at -$295000.0 in 2021, then soared by 117.63% to $52000.0 in 2022, then surged by 746.15% to $440000.0 in 2023, then surged by 47.95% to $651000.0 in 2024, then plunged by 97.24% to $18000.0 in 2025.
- Business Quant data shows KALV's Interest & Investment Income at $18000.0 in Q3 2025, $276000.0 in Q2 2025, and $651000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 18,000.00 |
| Apr 30, 2025 | 276,000.00 |
| Oct 31, 2024 | 651,000.00 |
| Jul 31, 2024 | 1.69 Mn |
| Apr 30, 2024 | 2.63 Mn |
| Jan 31, 2024 | 438,000.00 |
| Oct 31, 2023 | 440,000.00 |
| Jul 31, 2023 | 392,000.00 |
| Apr 30, 2023 | 1.42 Mn |
| Jan 31, 2023 | 658,000.00 |
| Oct 31, 2022 | 52,000.00 |
| Jul 31, 2022 | 98,000.00 |
| Apr 30, 2022 | -2.33 Mn |
| Jan 31, 2022 | 258,000.00 |
| Oct 31, 2021 | -295,000.00 |
| Jul 31, 2021 | -129,000.00 |
| Apr 30, 2021 | -1.06 Mn |
| Jan 31, 2021 | -48,000.00 |
| Oct 31, 2020 | -164,000.00 |
| Jul 31, 2020 | -5,000.00 |